LBIO (Longevity Biomedical) Debt-to-EBITDA : 0.00 (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Longevity Biomedical Debt-to-EBITDA?

Longevity Biomedical LBIO Debt-to-EBITDA is 0.00 as of . 20.

Debt-to-EBITDA measures a company's ability to pay off its debt.

Longevity Biomedical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was $0.00 Mil. Longevity Biomedical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was $0.00 Mil. Longevity Biomedical's annualized EBITDA for the quarter that ended in . 20 was $0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Longevity Biomedical's Debt-to-EBITDA or its related term are showing as below:

LBIO's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.255
* Ranked among companies with meaningful Debt-to-EBITDA only.

Longevity Biomedical  (NAS:LBIO) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Longevity Biomedical Debt-to-EBITDA Related Terms

Longevity Biomedical Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Longevity Biomedical's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longevity Biomedical Debt-to-EBITDA Chart

Longevity Biomedical Annual Data
Trend
Debt-to-EBITDA

Longevity Biomedical Semi-Annual Data
Debt-to-EBITDA

LBIO vs : Debt-to-EBITDA Comparison

For the Biotechnology subindustry, Longevity Biomedical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Longevity Biomedical Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longevity Biomedical's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Longevity Biomedical's Debt-to-EBITDA falls into.


Longevity Biomedical Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Longevity Biomedical's Debt-to-EBITDA for the fiscal year that ended in . 20 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=( + ) / N/A
=N/A

Longevity Biomedical's annualized Debt-to-EBITDA for the quarter that ended in . 20 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=( + ) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is one times the quarterly (. 20) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →
What does a Debt-to-EBITDA of 0.00 mean?
Longevity Biomedical (LBIO) has a Debt-to-EBITDA of 0.00 as of . 20. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Longevity Biomedical.
Is Longevity Biomedical's Debt-to-EBITDA too high?
Longevity Biomedical's current Debt-to-EBITDA is 0.00.
How does Longevity Biomedical's Debt-to-EBITDA compare to ?
Longevity Biomedical's Debt-to-EBITDA of 0.00 can be compared against companies in the Biotechnology industry. The industry median Debt-to-EBITDA is 1.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.26, based on 306 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Longevity Biomedical. For the Biotechnology industry, the median Debt-to-EBITDA is 1.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Longevity Biomedical's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longevity Biomedical stock overvalued right now?
Longevity Biomedical (LBIO) has a current Debt-to-EBITDA of 0.00. The current Debt-to-EBITDA is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Longevity Biomedical (LBIO), the current Debt-to-EBITDA is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Longevity Biomedical Business Description

Comparable Companies
Address 12100 NE 195th street, Suite 150, Bothell, WA, USA, 98011
Longevity Biomedical Inc is a clinical-stage biomedical company. The company is focused on the advancement of new technologies across therapeutics, monitoring, and digital health that aim to restore tissue form and function to increase health span. Longevity is acquiring a differentiated therapeutic pipeline of late-stage clinical technologies across ophthalmology, cardiovascular disease, and soft tissue reconstruction and repair.